Lightstone Ventures
Portola Valley, California, United StatesFounded 2012
Lightstone Ventures is a global life-science venture capital firm founded in 2012, investing in biotech and medtech companies pioneering breakthroughs in therapeutics and medical devices. The firm builds companies from start-up through commercialization, with offices in Portola Valley, Boston, and Dublin.
37% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $68.3M (across 70 rounds with reported amounts).
Portfolio
48
Fund Size
$375M
Top Stage
Series A
Last 12 Mo
4
Team
MC
Mike Carusi
Managing Partner
CG
Caroline G.
Partner
CI
Christina Isacson
Partner
CK
Christina K. Isacson
Partner
HG
Hanson Gifford
Partner
KN
Kenneth Noonan
Venture Partner
JW
Jingjing Wang
Vice President
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
81 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Crystalys Therapeutics Inc | Series B | $130M | Jul 2026 |
 Psithera | Series A | $47.5M | Dec 2025 |
| Crystalys Therapeutics Inc | Series A | $205M | Sep 2025 |
 Apreo Health | Series B | $130M | Sep 2025 |
 ProVerum Medical | Series B | — | Aug 2025 |
 Allay Therapeutics | Series D | $57.5M | Jun 2025 |
 Atsena Therapeutics | Series C | $150M | Apr 2025 |
| AAtsena | Series C | $150M | Apr 2025 |
 Reprieve Cardiovascular | Series B | $61M | Jan 2025 |
 Apreo Health | Series B | $130M | Jan 2025 |
| AApreo | Unknown | $130M | Jan 2025 |
 FIRE1 | Unknown | $120M | Jan 2025 |
| Atsena Therapeutics | Series C | $150M | Jan 2025 |
| PPROVERUM LIMITED | Series B | $80M | Jan 2025 |
| Apreo Health | Series B | $130M | Jan 2025 |
 Allay | Series D | $57.5M | Jan 2025 |
 Cala Health | Growth | $50M | Dec 2024 |
 Amber Therapeutics | Series A | $100M | Jun 2024 |
 Cerevance | Series C | $51M | Apr 2024 |
| Reprieve Cardiovascular | Series A | $42M | Jan 2024 |
| Amber Therapeutics | Series A | $100M | Jan 2024 |
 65LAB | Unknown | — | Oct 2023 |
 Tagworks Pharmaceuticals | Series A | $65M | Jun 2023 |
| TTagworks | Series A | $64M | Jun 2023 |
 Relievant MedSystems | Series G | $50M | Apr 2023 |
Page 1 of 4
Top Co-Investors
New Enterprise Associates14 shared
Gilde Healthcare10 shared
GV10 shared
Atlas Venture10 shared
Osage University Partners9 shared
Abingworth LLP9 shared
OrbiMed8 shared
Sofinnova Partners8 shared
RA Capital Management7 shared
Cormorant Asset Management7 shared
Endeavour Vision6 shared
F-Prime Capital6 shared
Intuitive Ventures6 shared
Canaan Partners6 shared
SR One6 shared
SV Health Investors6 shared
Novartis Venture Fund5 shared
Morgenthaler Ventures5 shared
Enterprise Ireland5 shared
Dementia Discovery Fund5 shared
Last updated: 7 October 2026